Tirzepatide is supplied as a dual gip/glp-1 receptor agonist peptide for qualified laboratory research. It is intended for laboratory studies of dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor signalling, receptor selectivity and incretin pathway biology. Available specifications: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 65 mg, 80 mg, 100 mg; 10 vials per box. For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.